CADL Candel Therapeutics, Inc.
Debt Financing ·
Candel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million.
Candel Therapeutics agreed on June 24, 2025 to sell 3,221,395 shares at $4.67 each in a registered direct offering. The prospectus names no placement agent or underwriter, and some buyers are directors and executive officers.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $30.5 million | $19.3 million |
| Net income (loss) | -$38.2 million | -$55.2 million |
| Cash from operations | -$38.3 million | -$27.0 million |
| Cash and equivalents | $119.7 million | $102.7 million |
Our latest story on this, dated Jun 24, 2025: "Candel Therapeutics agrees to sell about $15.0 million of stock in direct offering". The story links the filing or release it is based on. Read the story.
Candel Therapeutics, Inc. trades under the ticker CADL on NASDAQ.
Candel Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Candel Therapeutics, Inc. is 1841387. Its filings are on SEC EDGAR.
76,518,565 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Candel Therapeutics, Inc. under United States.
Our directory classifies Candel Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Candel Therapeutics, Inc. is US1374041093.
aibio.space lists Candel Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Candel Therapeutics, Inc. reported a net loss of $38.2 million for the fiscal year ended Dec 31, 2025, and used $38.3 million of cash in operations, per its annual report to the SEC.
$30.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$201.6 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Candel Therapeutics, dated Oct 14, 2025: "Candel signs Trinity Capital term loan of up to $130.0 million, draws $50.0 million". Candel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million. Source.
Our latest debt story, dated Oct 14, 2025: "Candel signs Trinity Capital term loan of up to $130.0 million, draws $50.0 million". Candel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million. Source.
Reported a financing. SEC Form 424B5. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.02,2.03,3.02,7.01,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio